logo
Footballer Savy King undergoes emergency heart surgery after terrifying collapse on pitch

Footballer Savy King undergoes emergency heart surgery after terrifying collapse on pitch

The Sun14-05-2025

ANGEL CITY star Savy King had emergency heart surgery after her shocking collapse during an NWSL game last week
King, 20, fell down during the second half of Friday's match between the Los Angeles outfit and the Utah Royals at the BMO Stadium in California.
2
2
The versatile defender received treatment while the rest of the players looked on, visibly shaken.
The former USA youth international was ultimately stretchered off after the game was stopped for 10 minutes.
Angel City announced the centre-back underwent the operation after doctors at Cedars-Sinai Medical Center in LA determined she had a heart abnormality
King's family announced she is currently recovering, and her prognosis 'is excellent.
A statement read: "On behalf of our entire family, along with Savy, we have been so moved by the love and support from Angel City players, staff, fans and community, as well as soccer fans across the country.
"We are blessed to share Savy is recovering well and we are looking forward to having her home with us soon."
A number of football personalities questioned the decision to continue the game after King's collapse.
USA and Washington Spirit ace Trinity Rodman wrote on her Instagram Stories: "In no world should that game have continued."
Royals manager Jimmy Coenraets also believes play should not have resumed.
Angel City found the courage to pull through and picked up a 2-0 victory.
Goals by Christen Press and Alyssa Thompson sealed the big win for the hosts.

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

US Open food and drink prices revealed as golf fans fume at ‘disgrace' of a menu and staggering cost of WATER
US Open food and drink prices revealed as golf fans fume at ‘disgrace' of a menu and staggering cost of WATER

The Sun

timean hour ago

  • The Sun

US Open food and drink prices revealed as golf fans fume at ‘disgrace' of a menu and staggering cost of WATER

GOLF fans fumed at the "disgrace" of a menu at the US Open. The tournament kicks off on Thursday but already the Oakmont concession prices have been revealed online. 3 3 And fans were stunned to see just how much a bite to eat could set them back. A Philly cheesesteak was the heftiest meal on the menu - costing $13.95 (£10.33) - while crisps were $3.49 (£2.58). A single Corona costs $11.95 (£8.85) - despite being able to buy a four-pack for £6 at Sainsbury's. Even a bottle of water is $4.95 (£3.66) - but what really did it for fans was the $1.95 (£1.44) price of a banana. One raged: "$1.98 for a banana??? I'm taking my business elsewhere!" Another fumed: "$1.95 for a banana is outrageous." One said: "$2 for a banana is crazy. Can get a bundle at the store for under $2!!! I am irate." On the course, American Bryson DeChambeau looks to retain his US Open title but Rory McIlroy enters off the back of his Masters win in April. Scottie Scheffler also claimed PGA Championship glory in May and will tee off as the bookies' favourite to go all the way. Elsewhere, fighting tooth and nail to make a name for himself in Pennsylvania will be full-time dentist Matt Vogt. Vogt - who runs his own dentistry practice in Indianapolis - is 1,173rd in the World Amateur Rankings but secured a debut place at a major. Not only does he hope his golf career will take off but also his dentistry business, revealing: "I think they've gotten a ton of enquiries. "I've got such a great team, I've got friends helping me out with all those messages and enquiries and said, 'hey, guys, forward those to Chris, my buddy, and make sure you stay focused on patients because that's what we're there to do in McCordsville, Indiana'. "It's been a lot of fun, some patients reaching out and fellow dentists. I feel like there are so many people behind me this week - Oakmont, Pittsburgh, dentistry - it's been fun. "Honestly, from a business perspective, that's not what it's about. We try to take good care of people, and if it brings us more great patients that we can help, awesome. "It will give us something to talk about maybe in and around the office." 3

Bombshell research shows weight-loss drugs like Ozempic don't work as well as companies boasted
Bombshell research shows weight-loss drugs like Ozempic don't work as well as companies boasted

Daily Mail​

time2 hours ago

  • Daily Mail​

Bombshell research shows weight-loss drugs like Ozempic don't work as well as companies boasted

Blockbuster weight loss drugs like Ozempic might not work as well as advertised, a bombshell study reveals. A Cleveland Clinic study found patients taking semaglutide and tirzepatide - the active ingredients in Ozempic, Wegovy and Mounjaro - lost up to 50 percent less weight than what drug companies reported in clinical trials. They were also 40 percent more likely to go off the drugs within a year than patients in trials for reasons such as side effects being too severe. In the new study, researchers looked at nearly 8,000 obese Americans who were prescribed either semaglutide or tirzepatide for a year. One in five stopped taking the drugs within three months and nearly one in three stopped before the end of the year. Patients in the new study lost anywhere from four to 12 percent of their body weight in a year depending on how long they stayed on the drugs. But in the drugs' clinical trials, they lost between 15 and 21 percent of their weight. The researchers said the disparity could be due to higher rates of patients stopping the drugs and patients using lower doses than those in clinical trials. Patients also complained of high drug costs and harsh side effects, which have included stomach paralysis and blindness in severe cases. Dr Hamlet Gasoyan, lead study author and researcher at Cleveland Clinic's Center for Value-Based Care, said: 'Our study shows that patients treated for obesity with semaglutide or trizepatide lost less weight on average in a regular clinical setting compared to what is observed in randomized clinical trials. 'According to our data, this could be explained by higher rates of discontinuation and lower maintenance dosages used in clinical practice, compared to randomized clinical trial settings.' About one in eight Americans report taking a GLP-1 agonist like Ozempic or Wegovy at some point in their lives. And recent research shows their popularity has soared 600 percent since 2019. The study, published Tuesday in Obesity Journal, looked at 7,881 adults patients obese patients using electronic health data. The majority (6,109) received semaglutide while the remainder took tirzepatide. It's unclear if they took specific brand names like Ozempic or Wegovy. The average participant age was 51 and three in four patients were women. Their average body mass index (BMI) was 39, which is considered 'severe obesity.' Any BMI over 30 is obese. Of those patients, 1,320 had prediabetes, a precursor to type 2 diabetes that affects 100million Americans, most of whom don't know they have it. Participants began taking semaglutide or tirzepatide for obesity between 2021 and 2023. Those that stopped taking the drugs within three months were considered 'early' discontinuers and those who stopped in three to 12 months were 'late' discontinuers. Researchers found about 20 percent of participants stopped taking the GLP-1 drugs early and 32 percent stopped late. Additionally, 80 percent were on lower maintenance doses than when they started. This was the equivalent of 1 mg or less of semaglutide or less than 7.5 mg of tirzepatide. A maintenence dose is the amount needed to sustain weight loss. After one year, people who stopped taking the drug early had a four percent weight reduction compared to seven percent for those who stopped late. The above graph shows weight reductions in patients who stopped taking weight loss drugs within three months, in three to 12 months and who never stopped Those who stayed on the drugs for the full year lost 12 percent, and participants who kept with the drugs and took higher maintenance dosages lost 14 percent body weight on semaglutide and 18 percent on tirzepatide. In semaglutide and tirzepatide's clinical trials, patients lost between 15 and 21 percent of their weight after one year, up to 50 percent less than those in the new study who stayed on the drugs for a year. The researchers believe participants lost less weight than those in clinical trials promoted by drug companies because they were more likely to stop taking the drugs, hampering their progress. They cited clinical trials showing patients discontinued the drugs at a rate of 17 percent, up to 40 percent less often. Patients in clinical trials were also more likely to take higher doses. Dr Gasoyan said: 'Our findings about the real-world use patterns of these medications and associated clinical outcomes could inform the decisions of healthcare providers and their patients on the role of treatment discontinuation and maintenance dosage in achieving clinically meaningful weight reductions.' The team found patients most commonly stopped taking weight loss drugs due to high costs, issues with insurance coverage, risk of side effects and medication shortages.

Dodgers score twice in 10th inning, hold off Padres
Dodgers score twice in 10th inning, hold off Padres

Reuters

time2 hours ago

  • Reuters

Dodgers score twice in 10th inning, hold off Padres

June 10 - Andy Pages' RBI double snapped a 10th-inning tie and lifted the visiting Los Angeles Dodgers to an 8-7 win over the San Diego Padres on Monday. Pages laced a 1-1 pitch from Wandy Peralta (3-1) to the left field wall, scoring Max Muncy, the automatic runner to start the inning. Tommy Edman added a run-scoring single off second base to provide a cushion. Kirby Yates (4-2) worked around a two-out walk in the ninth to earn the win, and Tanner Scott picked up his 12th save despite yielding a one-out RBI double to Jackson Merrill in the 10th. Scott got a popup from Gavin Sheets and a flyout from Xander Bogaerts to end it. Freddie Freeman finished with three of the Dodgers' 12 hits, while Pages and Edman each added two. Manny Machado was the only San Diego batter with two hits, while teammate Tyler Wade hit a three-run triple. Neither starter was involved in the decision. Los Angeles' Dustin May lasted five innings, permitting six hits and six runs, five earned, with four walks and a strikeout. San Diego's Nick Pivetta pitched four innings and yielded five runs, four earned, off eight hits and two walks with three strikeouts. Each team scored twice in the first. The Dodgers got their runs on Freeman's RBI double and Will Smith's sacrifice fly, while the Padres countered via Machado's run-scoring double and Merrill's sacrifice fly. San Diego took a 3-2 lead in the second when Jake Cronenworth scored from third on Smith's throwing error with two outs as the catcher tried to nab Fernando Tatis Jr. stealing second. That was followed by a wild third inning that saw each team plate three runs. The Dodgers tied it on Teoscar Hernandez's sacrifice fly and gained a 5-3 lead on Smith's sixth homer, a two-run blast to left that traveled an estimated 378 feet. But the Padres erased that deficit and went up 6-5 on Wade's bases-clearing triple, just past the sliding Hernandez in right-center. Los Angeles equalized in the fifth on a two-out RBI double into the right field corner by Hyeseong Kim. The Dodgers have won two games in a row while the Padres have dropped four of their past six. --Field Level Media

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store